

FORM PTO-1390 (REV 11-98)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER <b>2752-33</b>
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>09/Unknown/787000</b>
INTERNATIONAL APPLICATION NO. <b>PCT/EP99/07065</b>	INTERNATIONAL FILING DATE <b>22 September 1999</b>	PRIORITY DATE CLAIMED <b>24 September 1998</b>
TITLE OF INVENTION <b>IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE RESPIRATORY TRACT INFECTIONS (ARI)</b>		
APPLICANT(S) FOR DO/EO/US <b>GEERT et al.</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19 <sup>th</sup> month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has <b>NOT</b> expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (U.S.C. 371(c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).		
<b>Items 11. To 16. Below concern document(s) or information included:</b>		
11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information. <b>PTO-1449/ International Search Report/ Letter with 8 pages of Sequence listing and computer readable copy</b> <input type="checkbox"/> This application is entitled to "Small entity" status. <input type="checkbox"/> "Small entity" statement attached.		

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5)  
Unknown 09/1787000INTERNATIONAL APPLICATION NO.  
PCT/EP99/07065ATTORNEY'S DOCKET NUMBER  
2752-3317. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):**

- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....\$1000.00
- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....\$860.00
- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO .....\$710.00
- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$690.00
- International preliminary examination fee paid to USPTO (37 C.F.R. 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =**Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).**CALCULATIONS** PTO USE ONLY

\$ 860.00

\$ 0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total Claims	12	-20 =	0
Independent Claims	3	-3 =	0

MULTIPLE DEPENDENT CLAIMS(S) (if applicable)

\$270.00

\$ 0.00

**TOTAL OF ABOVE CALCULATIONS =**

\$ 860.00

Reduction by 1/2 for filing by small entity, if applicable. Small entity status must also be asserted. (Note 37 C.F.R. 1.9, 1.27, 1.28).

0.00

**SUBTOTAL =**

\$ 860.00

Processing fee of \$130.00, for furnishing the English Translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).

+

0.00

**TOTAL NATIONAL FEE =**

\$ 860.00

Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property

+

\$ 40.00

Fee for Petition to Revive Unintentionally Abandoned Application (\$1240.00 - Small Entity = \$620.00)

\$ 0.00

**TOTAL FEES ENCLOSED =**

\$ 900.00

Amount to be:  
refunded \$

Charged \$

- a. ☒ A check in the amount of \$900.00 to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 14-1140 in the amount of \$\_\_\_\_\_ to cover the above fees. A duplicate copy of this form is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed.
- d. ☐ The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.

**NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

**SEND ALL CORRESPONDENCE TO:**

NIXON & VANDERHYE P.C.  
1100 North Glebe Road, 8<sup>th</sup> Floor  
Arlington, Virginia 22201  
Telephone: (703) 816-4000

SIGNATURE

**B. J. Sadoff**

NAME

**36,663**

REGISTRATION NUMBER

**March 13, 2001**

Date

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

**Jannes**Atty. Ref.: **2551-58**Serial No. **09/787,000**

Group:

Filed: **March 13, 2001**

Examiner:

For: **Identification of Microorganisms Causing Acute  
Respiratory Tract Infections (ARI)**

\* \* \* \* \*

**July 2, 2001**Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**AMENDMENT**

Responsive to the Notification dated May 1, 2001, entry and consideration of the following amendments and remarks are requested.

**IN THE SPECIFICATION**

Please insert the attached replacement pages 15, 22 and 23 in place of the originally filed pages.

Insert the attached Sequence Listing for the copy of the same which was filed on March 13, 2001.

**REMARKS**

The specification has been amended to include sequence identifiers as well as the attached Sequence Listing. The attached paper and computer-readable copies of the Sequence Listing are the same.

**Jannes**  
**Serial No. 09/787,000**

A copy of the Notification of May 1, 2001, with the Error Report included with the same are attached and a copy of the Notification to Comply dated May 1, 2001, is attached.

No new matter has been added. A Letter to this affect is attached.

Marked up copies of the amended pages are attached.

An early and favorable Action on the merits is requested.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: 

**B. J. Sadoff**  
Reg. No. 36,663

**BJS:eaw**  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

1992; Hierholzer et al., 1993; Fan and Hendricksom, 1996). The sequences of probes used for the others are 5'-CCT GCA TTA ACA CTA AAT TC-3' (SEQ ID NO 1) for RSV; 5'-TCT TGC TAC CTT CTG TAC TAA-3' (SEQ ID NO 2) for *C. pneumonia* and 5'-AAA ATT CCA AAA GAG ACC GGC-3' (SEQ ID NO 3) for PIV-3. All capture probes were 3'-biotinylated and purchased by Eurogentec (Seraing, Belgium), Capture was allowed to proceed for 1 h at 37°C, and afterwards the wells were washed four times with 200 µl of washing solution (Boehringer Mannheim, Mannheim, Germany) at room temperature. To each well 200 µl of anti-DIG-peroxidase (10 mU/ml, Boehringer Mannheim, Mannheim, Germany) diluted 1/1,000 in a buffer containing 100 mM Tris-HCl, 150 mM NaCl (pH 7.5) was added. Plates were incubated for 30 min at 37°C and wells were washed four times with washing solution. 200 µl ABTS<sup>®</sup> substrate solution (Boehringer Mannheim, Mannheim, Germany) was added, and the wells were incubated for 30 min at 37°C. The optical density (OD) was read on a DIAS reader (Dynatech Laboratories, Guernsey, Channel Islands) at 405 nm (reference filter 492 nm). The run was considered valid, if all negative control values were less than 0.2 OD units and the positive control was higher than 1.0 OD units. Samples were classified as PCR positive or negative according to a cut-off OD value of 0.5 and by comparison with the results from gel electrophoresis. Samples with initial readings of between 0.2 and 0.5 were considered borderline and were classified as positive or negative only after retesting with the specific single primer set. Positive hybridization controls were included in each microwell hybridization assay. They consisted of PCR products derived from the positive controls that were included in the m-RT-PCR.

## 7. Administration of data

All data obtained were managed in a Microsoft Access database. This database included all available information about patients as well as all diagnostic data and results from m-RT-PCR-ELISA, and in case of influenza A and RSV the data of the EIA.

## 8. Bacterial and viral stocks

Bacterial and viral stocks used as positive control were kindly provided by the following persons: B. Schweiger and E. Schreier, (Robert-Koch-Institute, Berlin) enteroviruses, Influenza A and influenza B; K.M. Edwards (Vanderbilt University, Tennessee, USA) RSV, PIV-1, PIV-3; A. Strecker (Institute for Virology, Bochum) RSV-long, PIV-3; R. Krausse and P. Rautenberg (Institute for Medical Microbiology, Kiel), *M. pneumoniae*, *C. pneumoniae*, and adenoviruses.

The exact number of viruses or bacteria within these samples was not known and was assumed to be at most 10<sup>8</sup>/ml as stated by B. Schweiger and P. Rautenberg (personal

**Table 3.**

Organism	Original probe	Adapted versions*	Name**
Enterovirus	(SEQ ID NO:4) gaaacacggacacccaaagla	gaaacacggacacccaaagla (SEQ ID NO 4)	entero1
Influenza A	(SEQ ID NO:53) gicctcgcggaggactgaatgaatgat	catcgaggactgaatgg (SEQ ID NO 5)	influa1
Influenza B	(SEQ ID NO:6) gicacagacacccgattatcac	gicacagacacccgattatcac (SEQ ID NO 6)	influb1
Adenovirus	(SEQ ID NO:54) ctcgatgacgccgcggtgc	gatgacgccgcggtg (SEQ ID NO 7)	adeno1
		tcctgatgacgccgcg (SEQ ID NO 8)	adeno2
	(SEQ ID NO:55) tacctcattatcaatggtaagtaaatatg	cataaagaagggtgggc (SEQ ID NO 9)	adeno3
Parainfluenza 1		ccttcattatcaatggtaagtc (SEQ ID NO 10)	piv11
		ccttcattatcaatgggtatgc (SEQ ID NO 11)	piv12
		gtagaylaccttcattatcaatggt (SEQ ID NO 12)	piv13
Parainfluenza 3	(SEQ ID NO:13) aaaattccaaaagagacccggc	aaaattccaaaagagacccggc (SEQ ID NO 13)	piv31
RSV	(SEQ ID NO:1) ccgcattaaacactaaatc	cacctgcattaaacactaaatct (SEQ ID NO 14)	rsv1
<i>M. pneumoniae</i>	(SEQ ID NO:56) actctacggaggagcagta	ctacggaggagcagcagt (SEQ ID NO 15)	mpn1
<i>C. pneumoniae</i>	(SEQ ID NO:16) tctgtacctctctgiactaa	tctgtacctctctgiactaa (SEQ ID NO 16)	cpn1

\* y = c o r t

\*\* Probes in bold were used on first generation LIPA assay.

**Table 1: Comparison of EIA and m-RT-PCR-ELISA**

<b><i>RSV</i></b>	<b>EIA</b>			<b><i>InfA</i></b>	<b>EIA</b>		
		Pos.	Neg.			Pos.	Neg.
<b>PCR</b>	Pos.	116	25	<b>PCR</b>	Pos.	52	14
	Neg.	24	866		Neg.	1	873
	<b>Total</b>	140	891		<b>Total</b>	53	887

**Table 2. Primer sequences used in Example 1**

5	ENTERO-FP1:	att gtc acc ata agc agc ca-3'	(SEQ ID NO:35)
	ENTERO-RP1:	tcc tcc ggc ccc tga atg cg-3'	(SEQ ID NO:36)
10	MPN-FP1:	aag gac ctg caa ggg ttc gt-3'	(SEQ ID NO:37)
	MPN-RP1:	ctc tag cca tta cct gct aa-3'	(SEQ ID NO:38)
	INFLUA-FP1:	aag ggc ttt cac cga aga gg-3'	(SEQ ID NO:39)
	INFLUA-RP1:	ccc att ctc att act gct tc-3'	(SEQ ID NO:40)
15	INFLUB-FP1:	atg gcc atc gga tcc tca ac-3'	(SEQ ID NO:41)
	INFLUB-RP1:	tgt cag cta tta tgg agc tg-3'	(SEQ ID NO:42)
	ADENO-FP1:	gcc gag aag ggc gtg cgc agg ta-3'	(SEQ ID NO:43)
20	ADENO-RP1:	atg act ttt gag gtg gat ccc atg ga-3'	(SEQ ID NO:44)
	CPN-FP1:	tga caa ctg tag aaa tac agc-3'	(SEQ ID NO:45)
	CPN-RP1:	cgc ctc tct cct ata aat-3'	(SEQ ID NO:46)
25	PIV1-FP1:	cac atc ctt gag tga tta agt ttg atg a-3'	(SEQ ID NO:47)
	PIV1-RP1:	att tct gga gat gtc ccg tag gag aac-3'	(SEQ ID NO:48)
	PIV3-FP1:	tag cag tat tga agt tgg ca-3'	(SEQ ID NO:49)
	PIV3-RP1:	aga ggt caa tac caa caa cta-3'	(SEQ ID NO:50)
30	RSV-FP1:	tgt tat agg cat atc att ga-3'	(SEQ ID NO:51)
	RSV-RP1:	tta acc agc aaa gtg tta ga-3'	(SEQ ID NO:52)

Marked up  
copy

1992; Hierholzer et al., 1993; Fan and Hendricksom, 1996). The sequences of probes used for the others are 5'-CCT GCA TTA ACA CTA AAT TC-3' (SEQ ID NO 1) for RSV; 5'-TCT TGC TAC CTT CTG TAC TAA-3' (SEQ ID NO 2) for *C. pneumonia* and 5'-AAA ATT CCA AAA GAG ACC GGC-3' (SEQ ID NO 3) for PIV-3. All capture probes were 3'-biotinylated and purchased by Eurogentec (Seraing, Belgium), Capture was allowed to proceed for 1 h at 37°C, and afterwards the wells were washed four times with 200 µl of washing solution (Boehringer Mannheim, Mannheim, Germany) at room temperature. To each well 200 µl of anti-DIG-peroxidase (10 mU/ml, Boehringer Mannheim, Mannheim, Germany) diluted 1/1,000 in a buffer containing 100 mM Tris-HCl, 150 mM NaCl (pH 7.5) was added. Plates were incubated for 30 min at 37°C and wells were washed four times with washing solution. 200 µl ABTS® substrate solution (Boehringer Mannheim, Mannheim, Germany) was added, and the wells were incubated for 30 min at 37°C. The optical density (OD) was read on a DIAS reader (Dynatech Laboratories, Guernsey, Channel Islands) at 405 nm (reference filter 492 nm). The run was considered valid, if all negative control values were less than 0.2 OD units and the positive control was higher than 1.0 OD units. Samples were classified as PCR positive or negative according to a cut-off OD value of 0.5 and by comparison with the results from gel electrophoresis. Samples with initial readings of between 0.2 and 0.5 were considered borderline and were classified as positive or negative only after retesting with the specific single primer set. Positive hybridization controls were included in each microwell hybridization assay. They consisted of PCR products derived from the positive controls that were included in the m-RT-PCR.

## 7. Administration of data

All data obtained were managed in a Microsoft Access database. This database included all available information about patients as well as all diagnostic data and results from m-RT-PCR-ELISA, and in case of influenza A and RSV the data of the EIA.

## 8. Bacterial and viral stocks

Bacterial and viral stocks used as positive control were kindly provided by the following persons: B. Schweiger and E. Schreier, (Robert-Koch-Institute, Berlin) enteroviruses, Influenza A and influenza B; K.M. Edwards (Vanderbilt University, Tennessee, USA) RSV, PIV-1, PIV-3; A. Strecker (Institute for Virology, Bochum) RSV-long, PIV-3; R. Krausse and P. Rautenberg (Institute for Medical Microbiology, Kiel), *M. pneumoniae*, *C. pneumoniae*, and adenoviruses.

The exact number of viruses or bacteria within these samples was not known and was assumed to be at most 10<sup>8</sup>/ml as stated by B. Schweiger and P. Rautenberg (personal



marked - vj  
copy

**Table 1: Comparison of EIA and m-RT-PCR-ELISA**

<u>RSV</u>	<u>EIA</u>			<u>InfA</u>	<u>EIA</u>		
		Pos.	Neg.			Pos.	Neg.
PCR	Pos.	116	25	PCR	Pos.	52	14
	Neg.	24	866		Neg.	1	873
	Total	140	891		Total	53	887

**Table 2. Primer sequences used in Example 1**

ENTERO-FP1: att gtc acc ata agc agc ca-3' (SEQ ID NO: 35)

ENTERO-RP1: tcc tcc ggc ccc tga atg cg-3' (SEQ ID NO: 36)

MPN-FP1: aag gac ctg caa ggg ttc gt-3' (SEQ ID NO: 37)

MPN-RP1: ctc tag cca tta cct gct aa-3' (SEQ ID NO: 38)

INFLUA-FP1: aag ggc ttt cac cga aga gg-3' (SEQ ID NO: 39)

INFLUA-RP1: ccc att ctc att act gct tc-3' (SEQ ID NO: 40)

INFLUB-FP1: atg gcc atc gga tcc tca ac-3' (SEQ ID NO: 41)

INFLUB-RP1: tgt cag cta tta tgg agc tg-3' (SEQ ID NO: 42)

ADENO-FP1: gcc gag aag ggc gtg cgc agg ta-3' (SEQ ID NO: 43)

ADENO-RP1: atg act ttt gag gtg gat ccc atg ga-3' (SEQ ID NO: 44)

CPN-FP1: tga caa ctg tag aaa tac agc-3' (SEQ ID NO: 45)

CPN-RP1: cgc ctc tct cct ata aat-3' (SEQ ID NO: 46)

PIV1-FP1: cac atc ctt gag tga tta agt ttg atg a-3' (SEQ ID NO: 47)

PIV1-RP1: att tct gga gat gtc ccg tag gag aac-3' (SEQ ID NO: 48)

PIV3-FP1: tag cag tat tga agt tgg ca-3' (SEQ ID NO: 49)

PIV3-RP1: aga ggt caa tac caa caa cta-3' (SEQ ID NO: 50)

RSV-FP1: tgt tat agg cat atc att ga-3' (SEQ ID NO: 51)

RSV-RP1: tta acc agc aaa gtg tta ga-3' (SEQ ID NO: 52)

marked - v f  
copy

Table 3.

Organism	Original probe	Adapted versions*	Name**
Enterovirus	(SEQ ID NO:14) gaaacaggacacccaaagla	gaaacaggacacccaaagla (SEQ ID NO 4)	entero1
Influenza A	(SEQ ID NO:15) gicctcagggaggactgaatgat	calcgaggactgaatgg (SEQ ID NO 5)	influa1
Influenza B	(SEQ ID NO:16) gicacagacacgattatcac	gicacagacacgattatcac (SEQ ID NO 6)	influb1
Adenovirus	(SEQ ID NO:17) gicacagacacgattatcac (SEQ ID NO:18) cicgatgacgcgcgggfc	gatgacgcgcgggtg (SEQ ID NO 7) tcctgatgacgcgcgg (SEQ ID NO 8)	adeno1
			adeno2
			adeno3
Parainfluenza 1	(SEQ ID NO:19) taccctcattatcaatggtaagtaataatg	cataaagagggtgggc (SEQ ID NO 9) ccctcattatcaatggtaagtc (SEQ ID NO 10) ccctcattatcaatgggtg (SEQ ID NO 11)	piv11 piv12 piv13
Parainfluenza 3	(SEQ ID NO:20) aaaattccaaaagagaccggc	gtagaytaccttcattatcaatggt (SEQ ID NO 12)	piv31
RSV	(SEQ ID NO:21) ccctgcattaacacacaaatct	aaaattccaaaagagaccggc (SEQ ID NO 13) caccctgcattaacacacaaatct (SEQ ID NO 14)	rsv1
<i>M. pneumoniae</i>	(SEQ ID NO:22) actcgtacggaggagcagcagla	ctacggaggagcagcagc (SEQ ID NO 15)	mpn1
<i>C. pneumoniae</i>	(SEQ ID NO:23) tcctgtaccttcgtactaa	tcctgtaccttcgtactaa (SEQ ID NO 16)	cpn1

\* y = c or t

\*\* Probes in bold were used on first generation LIPA assay.

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

**JANNES et al**

Atty. Ref.: 2551-58

Serial No. 09/787,000

Group:

Filed: March 13, 2001

Examiner:

For: **Identification of Microorganisms Causing Acute  
Respiratory Tract Infections (ARI)**

\* \* \* \* \*

July 2, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**LETTER**

The attached paper and computer-readable copies of the Sequence Listing are the same. No new matter has been added.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



**B. J. Sadoff**

Reg. No. 36,663

**BJS:eaw**

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

## SEQUENCE LISTING

<110> JANNES, GEERT  
SCHMITT, HEINZ-JOSEF

<120> IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE  
RESPIRATORY TRACT INFECTIONS (ARI)

<130> 2752-33

<140> 09/787,000

<141> 2001-03-13

<150> PCT/EP99/07065

<151> 1999-09-22

<150> EP 98870203.1

<151> 1998-09-24

<160> 56

<170> PatentIn Ver. 2.1

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
probe

<400> 1

cctgcattaa cactaaattc

20

<210> 2

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
probe

<400> 2

tcttgctacc ttctgtacta a

21

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
probe

<400> 3  
aaaattccaa aagagaccgg c 21

<210> 4  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
probe

<400> 4  
gaaacacgga cacccaaagt a 21

<210> 5  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
probe

<400> 5  
catcggagga cttgaatgg 19

<210> 6  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
probe

<400> 6  
gtcaagagca ccgattatca c 21

<210> 7  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
probe

<400> 7  
gatgacgccg cggtg 15

<210> 8  
<211> 16

<212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 8  
 tctcgatgac gccgcg 16

<210> 9  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 9  
 cataaagaag ggtgggc 17

<210> 10  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 10  
 ccttcattat caattggtaa gtc 23

<210> 11  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 11  
 ccttcattat caattgggtga tgc 23

<210> 12  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 12  
gtagaytac cttcattatc aattggt 27

<210> 13  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
probe

<400> 13  
aaaattccaa aagagaccgg c 21

<210> 14  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
probe

<400> 14  
cacctgcatt aacactaaat tct 23

<210> 15  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
probe

<400> 15  
ctacgggagg cagcagt 17

<210> 16  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
probe

<400> 16  
tcttgctacc ttctgtacta a 21

<210> 17  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic primer

<400> 17  
 ggtggatcac ctcctttcta atg 23

<210> 18  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic primer

<400> 18  
 gtggtaaatt aaaccctaat ccc 23

<210> 19  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic primer

<400> 19  
 gcatccacca taagccctta g 21

<210> 20  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic primer

<400> 20  
 cctttttaag gacaaggaag gttg 24

<210> 21  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence



<220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 21

gatccatgca agttaacttc acc

23

<210> 22

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 22

tatagctgct ggatcggtgg

20

<210> 23

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 23

cctaaaccga acgcttaaca c

21

<210> 24

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 24

ggtaaattaa acccaaattcc ct

22

<210> 25

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 25

gaacatttcc gcttctttc

19

<210> 26  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 26  
 gaacatttcc gcttctttca a 21

<210> 27  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 27  
 gcaagtattt tatattccgc att 23

<210> 28  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 28  
 gttttcaaaa cattcagtat atgac 26

<210> 29  
 <211> 16  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 29  
 gcctgtccag aggatg 16

<210> 30  
 <211> 17  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 30  
 cccgtcttga agatggg 17

<210> 31  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 31  
 ttaacatrta agtgcttama g 21

<210> 32  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 32  
 cctgcattr cactaaattc 20

<210> 33  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 33  
 cacctgcatt racactaaat tc 22

<210> 34  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 probe

<400> 34  
cttacacctg cattract aaattc 26

<210> 35  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 35  
attgtcacca taagcagcca 20

<210> 36  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 36  
tcctccggcc cctgaatgcg 20

<210> 37  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 37  
aaggacctgc aagggttcgt 20

<210> 38  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 38  
ctctagccat tacctgctaa 20

<210> 39  
<211> 20

<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 39  
aagggtttc accgaagagg 20

<210> 40  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 40  
cccattctca ttactgcttc 20

<210> 41  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 41  
atggccatcg gatcctcaac 20

<210> 42  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 42  
tgtcagctat tatggagctg 20

<210> 43  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 43  
gccgagaagg gcgtgcgcag gta

23

<210> 44  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 44  
atgacttttg aggtggatcc catgga

26

<210> 45  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 45  
tgacaactgt agaaatacag c

21

<210> 46  
<211> 18  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 46  
cgcctctctc ctataaat

18

<210> 47  
<211> 28  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Synthetic  
primer

<400> 47  
cacatccttg agtgattaag tttgatga

28

<210> 48  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 primer

<400> 48  
 atttctggag atgtcccgtg ggagaac 27

<210> 49  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 primer

<400> 49  
 tagcagtatt gaagttggca 20

<210> 50  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 primer

<400> 50  
 agaggtcaat accaacaact a 21

<210> 51  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Synthetic  
 primer

<400> 51  
 tggtataggc atatcattga 20

<210> 52  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic primer

<400> 52

ttaaccagca aagtgttaga

20

<210> 53

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 53

gtcctcatcg gaggacttga atggaatgat

30

<210> 54

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 54

ctcgatgacg ccgcggtgc

19

<210> 55

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 55

taccttcatt atcaattggt aagtcaatat atg

33

<210> 56

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic probe

<400> 56

actcctacgg gaggcagcag ta

22



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

GEERT et al.

Atty. Ref.: 2752-33

Serial No. Unknown

Group:

Filed: March 13, 2001

Examiner:

For: IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE RESPIRATORY  
TRACT INFECTIONS (ARI)

\* \* \* \* \*

March 13, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

**PRELIMINARY AMENDMENT**

Preliminarily amend the above-identified application as follows.

**IN THE SPECIFICATION:**

Amend the specification as follows:

Insert the attached Sequence Listing after the figures.

**IN THE CLAIMS:**

Amend the claims as follows:

3. (Amended) Method according to claim 1 wherein in addition also at least one primer pair for the specific detection of *B. pertussis* and *B. parapertussis* are used.

4. (Amended) Method according to claim 1 wherein said primers are chosen from Table 2 of Table 4.

GEERT et al.  
Serial No. Unknown  
Attny Dkt: 2752-33

5. (Amended) Method according to claim 1 wherein said amplified products are subsequently detected using a probe, with said probe being preferably selected from Table 3, Table 4 or Table 5.

8. (Amended) Kit for the detection of acute respiratory tract infection comprising a set of primers for performing a method according to claim 1.

**REMARKS**

The claims have been amended, without prejudice, to reduce the claims fees.

The attached paper and computer readable copies of the Sequence Listing are the same.


No new matter has been added.

An early and favorable Action on the merits is requested.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_



B. J. Sadoff  
Reg. No. 36,663

BJS:ms  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**MARKED-UP COPY OF AMENDED CLAIMS**

3. (Amended) Method according to claim 1 [or 2] wherein in addition also at least one primer pair for the specific detection of *B. pertussis* and *B. parapertussis* are used.

4. (Amended) Method according to [any of claims 1 to 3] claim 1 wherein said primers are chosen from Table 2 of Table 4.

5. (Amended) Method according to [claims 1 to 4] claim 1 wherein said amplified products are subsequently detected using a probe, with said probe being preferably selected from Table 3, Table 4 or Table 5.

8. (Amended) Kit for the detection of acute respiratory tract infection comprising a set of primers for performing a method according to [any of claims 1 to 4] claim 1.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

GEERT et al.

Atty. Ref.: 2752-33

Serial No. Unknown

Group:

Filed: March 13, 2001

Examiner:

For: IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE RESPIRATORY  
TRACT INFECTIONS (ARI)

\* \* \* \* \*

March 13, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**LETTER**

The attached paper and computer readable copies of the Sequence Listing are the same. No new matter has been added.

Respectfully submitted,

**NIXON & VANDERHYE P.C.**By: B. J. Sadoff  
Reg. No. 36,663BJS:ms  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

SEQUENCE LISTING

<110> JANNES, GEERT  
SCHMITT, HEINZ-JOSEF

<120> IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE  
RESPIRATORY TRACT INFECTIONS (ARI)

<130> 2752-33

<140> Unassigned

<141> 2001-03-12

<150> PCT/EP99/07065

<151> 1999-09-22

<150> EP98870203.1

<151> 1998-09-24

<160> 34

<170> PatentIn Ver. 2.1

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 1

cctgcattaa cactaaattc

20

<210> 2

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 2

ttctgtacc ttctgtacta a

21

<210> 3

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 3

aaaattccaa aagagaccgg c

21

<210> 4  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 4  
gaaacacgga cacccaaagt a 21

<210> 5  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 5  
catcggagga cttgaatgg 19

<210> 6  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 6  
gtcaagagca ccgattatca c 21

<210> 7  
<211> 15  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 7  
gatgacgccg cggtg 15

<210> 8  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 8  
tctcgatgac gccgcg 16

<210> 9  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 9  
cataaagaag ggtgggc 17

<210> 10  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 10  
ccttcattat caattggtaa gtc 23

<210> 11  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 11  
ccttcattat caattggtga tgc 23

<210> 12  
<211> 27  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 12  
gttagaytac cttcattatc aattggt 27

<210> 13  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide  
  
<400> 13  
aaaattccaa aagagaccg c 21

<210> 14  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide  
  
<400> 14  
cacctgcatt aacactaaat tct 23

<210> 15  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide  
  
<400> 15  
ctacgggagg cagcagt 17

<210> 16  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide  
  
<400> 16  
tcttgctacc ttctgtacta a 21

<210> 17  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide  
  
<400> 17  
ggtggatcac ctcttttcta atg 23

<210> 18



<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 18  
gtggtaaatt aaacccaaatt ccc 23

<210> 19  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 19  
gcatccacca taagccctta g 21

<210> 20  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 20  
cctttttaag gacaaggaag gttg 24

<210> 21  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 21  
gatccatgca agttaacttc acc 23

<210> 22  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 22  
tatagctgct ggatcggtgg 20

<210> 23  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 23  
ccaaaaccca acgcttaaca c 21

<210> 24  
<211> 22  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 24  
ggtaaattaa acccaaattcc ct 22

<210> 25  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 25  
gaacatttcc gcttcttttc 19

<210> 26  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 26  
gaacatttcc gcttctttca a 21

<210> 27  
<211> 23  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 27  
gcaagtattt tatattccgc att 23

<210> 28  
<211> 26  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 28  
gttttcaaaa cattcagtat atgata 26

<210> 29  
<211> 16  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 29  
gcctgtccag aggatg 16

<210> 30  
<211> 17  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 30  
cccgtcttga agatggg 17

<210> 31  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:oligonucleotide

<400> 31  
ttaacatrra agtgcttama g 21

<210> 32  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 32

cctgcattr cactaaattc

20

<210> 33

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 33

cacctgcatt racactaaat tc

22

<210> 34

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide

<400> 34

cttacacctg catracact aaattc

26

IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE RESPIRATORY TRACT INFECTIONS (ARI)

The present invention relates to the field of detection of microorganisms, more particularly detection of acute respiratory tract infections.

Acute respiratory tract infections (ARIs) are the most common cause of childhood morbidity and mortality world-wide, accounting for about 30 % of all childhood deaths in the developing world (Hinman *et al.*, 1998). While rarely causing death in industrialized countries, ARIs cause enormous direct and indirect health care costs (Garenne *et al.*, 1992; UNICEF, 1993; Dixon, 1985). The causative agents of ARIs encompass a wide variety of microorganisms. *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Moraxella catarrhalis* (Barlett and Mundy, 1995) are the most common bacteria encountered. As commensals of the upper respiratory tract the usually contaminate sputum samples, nasopharyngeal aspirates or swabs and thus their etiological role in ARIs is difficult to prove by upper respiratory tract sampling, unless invasive techniques (lung puncture) are used (Trolfors and Claesson, 1997; Nohynek *et al.*, 1995).

In contrast to these bacteria, detection of *Mycoplasma pneumoniae*, *Chlamydia pneumoniae* and also the detection of viruses in a child with respiratory symptoms is usually considered as evidence of acute infection. Current methods to identify these agents include cell culture, rapid antigen detection assays, serology (indirectly) and recently, PCR (Trolfors and Claesson, 1997; Saikku, 1997). Cell culture techniques require specialized laboratories, are expensive, time consuming and labour intensive. Rapid antigen assays are available for a few microorganisms only (influenza A and RSV in most countries). Serology usually requires documentation of a rise of antibody concentration from an acute to a convalescent blood sample and thus test results come in too late to be of relevance for the treatment of acute disease. While currently no rapid method for microbiological diagnosis of ARI is available for routine use, availability of such a test could result in less and more precisely tailored antibiotic therapies, resulting in reduced costs, less side effects as well as in a reduction of the emergence of resistance (Woo *et al.*, 1997).

Currently available nucleic acid amplification techniques such as PCR (Saiki *et al.*, 1988) and RT-PCR are highly sensitive techniques for the detection of nucleic acid sequences from viruses and bacteria in clinical specimens (Saiki, 1990; Kawasaki, 1990). These amplification techniques are particularly advantageous for detecting fastidious or "difficult to culture" organisms such as the respiratory syncytial virus (Paton *et al.*, 1992) or *M. pneumoniae* (Van Kuppeveld *et al.*, 1992).

Previous studies using PCR and RT-PCR for the diagnosis of ARIs have focused on the detection of a single virus or bacterium; however, the diagnostic utility of nucleic acid amplification techniques for a single infectious agent is limited by the inability to establish a specific aetiology whenever the result is negative and by the inability to document simultaneous infections involving more than one infectious organism.

Published multiplex-PCR assays for the simultaneous detection of pathogens (Hassan-King *et al.*, 1996, 1998; Messmer *et al.*, 1997) and multiplex-RT-PCR panel to respiratory specimens as described by Gilbert *et al.* (1996) has the disadvantage of different and time consuming assay conditions for each detected organism and the use of several tubes for one sample, thus enlarging the risk of cross-contamination.

Our strategy to overcome these limitations was to use a multiplex -RT-PCR protocol that allows the simultaneous detection of respiratory pathogens within one working day including RNA-viruses (enteroviruses, influenza A and B viruses, parainfluenzavirus type 1 and 3, respiratory syncytial virus), a DNA-virus (adenovirus) and *bacteria* (*C. pneumoniae*, *M. pneumoniae*) that do not usually colonize the upper respiratory tract of children.

The aim of the present invention is to provide methods and kits for detecting acute respiratory tract infections.

More particularly it is an aim of the present invention to provide a multiplex PCR method and kit for detecting acute respiratory tract infections.

It is also an aim of the present invention to provide primers and probes useful for detecting acute respiratory tract infections.

More particularly the present invention relates to a method for the detection of acute respiratory tract infection comprising the simultaneous amplification of several target nucleotide sequences present in a biological sample by means of a primer mixture comprising at least one primer set from each one of the following gene regions:

- the F1 subunit of the fusion glycoprotein gene for RSV,
- the hemagglutininneuraminidase gene for PIV-1,
- the 5' noncoding region of the PIV-3 fusion protein gene,
- 16 S rRNA sequence for *M. pneumoniae*,
- 16S rRNA sequence for *C. pneumoniae*,
- the 5' noncoding region for enterovirus,
- the non-structural protein gene from influenza A,
- the non-structural protein gene from influenza B, and,
- the hexon gene for adenoviruses.

This multiplex RT-PCR method is particularly preferred because it allows to determine the presence of the following micro organisms which infect the respiratory tract of mainly children in one amplification step: RSV, parainfluenza virus, *M. pneumoniae*, *C. pneumoniae*, enterovirus, influenza A and B and adenoviruses.

5 According to an alternative embodiment, the present invention also relates to a method as defined above in which human parainfluenza virus, influenza A and B, RSV and at least one of the following micro organisms are detected by means of a multiplex RT-PCR using primer pairs from the regions specified above: *M. pneumoniae*, *C. pneumoniae*, enterovirus or adenovirus.

10 According to an alternative embodiment, the present invention also relates to a method as defined above in which human parainfluenza virus, influenza A and B, RSV and at least one of the following micro organisms are detected by means of RT-PCR using primer pairs from the regions specified above: *M. pneumoniae*, *C. pneumoniae*, enterovirus or adenovirus.

15 According to a preferred embodiment, the present invention relates to a method as defined above wherein said 16S rRNA primers are replaced by primers from the spacer region between the 16S and the 23S rRNA sequences.

According to another embodiment, the present invention relates to a method as defined above wherein in addition also at least one primer pair for the specific detection of *B. pertussis* and *B. parapertussis* are used, with said primers being preferably from the spacer region between the 16S and 23S rRNA sequences.

20 According to another embodiment, the present invention relates to a method as defined above wherein said primers are chosen from Table 2 or Table 4.

According to another embodiment, the present invention relates to a method as defined above wherein said amplified products are subsequently detected using a probe, with said probe being preferably selected from Table 3, Table 4 or Table 5.

25 According to another embodiment the present invention relates to a primer chosen from Table 2 or Table 4. The present invention also relates to the use of such a primer in a method as defined above. The invention also relates to a method for preparing a primer according to the invention.

30 According to another embodiment, the present invention relates to a probe chosen from Table 3, Table 4, or Table 5. The present invention also relates to the use of such a probe in a method as defined above. The invention also relates to a method for preparing a probe according to the invention. The primers and probes of the invention can be varied as specified below.

35

According to another embodiment, the present invention relates to a kit for the detection of acute respiratory tract infection comprising a set of primers as defined above for performing a method as defined above. Besides said primers, such a kit may also contain probes as well as the necessary buffers for achieving the amplification and possible hybridization reactions as well as a kit insert. The present invention also relates to a kit as defined above containing at least one of the probes as defined above.

According to another embodiment, the present invention relates to a kit for the detection of acute respiratory tract infection comprising a set of probes for performing a method as defined above. Besides said probes, such a kit may also contain primers as well as the necessary buffers for achieving the hybridization and possible amplification reactions as well as a kit insert. The present invention also relates to a kit as defined above containing at least one of the primers as defined above.

According to another embodiment, the present invention relates to a kit as defined above, wherein said probes are applied as parallel lines on a solid support, preferably on a nylon membrane, preferably a LiPA kit (see examples section and below).

Different techniques can be applied to perform the methods of the present invention. These techniques may comprise immobilizing the target polynucleic acids, after amplification, on a solid support and performing hybridization with labelled oligonucleotide probes. Alternatively, the probes may be immobilized on a solid support and hybridization may be performed with labelled target polynucleic acids, possibly after amplification. This technique is called reverse hybridization. A convenient reverse hybridization technique is the line probe assay (LiPA, Innogenetics, Belgium). This assay uses oligonucleotide probes immobilized as parallel lines on a solid support strip. Alternatively the probes may be present on an array or micro-array format. The probes can be spotted onto this array or synthesized in situ on the array (Lockhart *et al.*, 1996) in discrete locations. It is to be understood that any other technique for detection of the above-mentioned co-amplified target sequences also covered by the present invention. Such a technique can involve sequencing or other array methods known in the art.

The following definitions and explanations will permit a better understanding of the present invention.

The target material in the samples to be analysed may either be DNA or RNA, e.g. genomic DNA, messenger RNA or amplified versions thereof. These molecules are in this application also termed "polynucleic acids".

Well-known extraction and purification procedures are available for the isolation of RNA or DNA from a sample (e.g. in Sambrook *et al.*, 1989).



The term "probe" according to the present invention refers to a single-stranded oligonucleotide which is designed to specifically hybridize to the target polynucleic acids.

Preferably, the probes of the invention are about 5 to 50 nucleotides long, more preferably from about 10 to 25 nucleotides. Particularly preferred lengths of probes include 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides. The nucleotides as used in the present invention may be ribonucleotides, deoxyribonucleotides and modified nucleotides such as inosine or nucleotides containing modified groups which do not essentially alter their hybridization characteristics.

The term "primer" refers to a single stranded oligonucleotide sequence capable of acting as a point of initiation for synthesis of a primer extension product which is complementary to the nucleic acid strand to be copied. The length and the sequence of the primer must be such that they allow to prime the synthesis of the extension products. Preferably the primer is about 5-50 nucleotides long. Specific length and sequence will depend on the complexity of the required DNA or RNA targets, as well as on the conditions at which the primer is used, such as temperature and ionic strength. It is to be understood that the primers of the present invention may be used as probes and *vice versa*, provided that the experimental conditions are adapted.

The expression "suitable primer pair" in this invention refers to a pair of primers allowing specific amplification of a specific target polynucleic acid fragment.

The term "target region" of a probe or a primer according to the present invention is a sequence within the polynucleic acids to be detected to which the probe or the primer is completely complementary or partially complementary (i.e. with some degree of mismatch). It is to be understood that the complement of said target sequence is also a suitable target sequence in some cases.

"Specific hybridization" of a probe to a target region of a polynucleic acid means that said probe forms a duplex with part of this region or with the entire region under the experimental conditions used, and that under those conditions said probe does not form a duplex with other regions of the polynucleic acids present in the sample to be analysed.

"Specific hybridization" of a primer to a target region of a polynucleic acid means that, during the amplification step, said primer forms a duplex with part of this region or with the entire region under the experimental conditions used, and that under those conditions said primer does not form a duplex with other regions of the polynucleic acids present in the sample to be analysed. It is to be understood that "duplex" as used hereby, means a duplex that will lead to specific amplification.

The fact that amplification primers do not have to match exactly with the corresponding target sequence in the template to warrant proper amplification is amply

documented in the literature (Kwok *et al.*, 1990). However, when the primers are not completely complementary to their target sequence, it should be taken into account that the amplified fragments will have the sequence of the primers and not of the target sequence. Primers may be labelled with a label of choice (e.g. biotin). The amplification method used can be either polymerase chain reaction (PCR; Saiki *et al.*, 1988), ligase chain reaction (LCR; Landgren *et al.*, 1988; Wu & Wallace, 1989; Barany, 1991), nucleic acid sequence-based amplification (NASBA; Guatelli *et al.*, 1990; Compton, 1991), transcription-based amplification system (TAS; Kwoh *et al.*, 1989), strand displacement amplification (SDA; Duck, 1990) or amplification by means of Q $\beta$  replicase (Lomeli *et al.*, 1989) or any other suitable method to amplify nucleic acid molecules known in the art.

Probe and primer sequences are represented throughout the specification as single stranded DNA oligonucleotides from the 5' to the 3' end. It is obvious to the man skilled in the art that any of the below-specified probes can be used as such, or in their complementary form, or in their RNA form (wherein T is replaced by U).

The probes according to the invention can be prepared by cloning of recombinant plasmids containing inserts including the corresponding nucleotide sequences, if need be by excision of the latter from the cloned plasmids by use of the adequate nucleases and recovering them, e.g. by fractionation according to molecular weight. The probes according to the present invention can also be synthesized chemically, for instance by the conventional phospho-triester method.

The oligonucleotides used as primers or probes may also comprise nucleotide analogues such as phosphorothiates (Matsukura *et al.*, 1987), alkylphosphorothiates (Miller *et al.*, 1979) or peptide nucleic acids (Nielsen *et al.*, 1991, 1993) or may contain intercalating agents (Asseline *et al.*, 1984). As most other variations or modifications introduced into the original DNA sequences of the invention these variations will necessitate adaptations with respect to the conditions under which the oligonucleotide should be used to obtain the required specificity and sensitivity. However the eventual results of hybridization will be essentially the same as those obtained with the unmodified oligonucleotides. The introduction of these modifications may be advantageous in order to positively influence characteristics such as hybridization kinetics, reversibility of the hybrid-formation, biological stability of the oligonucleotide molecules, etc.

The term "solid support" can refer to any substrate to which an oligonucleotide probe can be coupled, provided that it retains its hybridization characteristics and provided that the background level of hybridization remains low. Usually the solid substrate will be a microtiter plate, a membrane (e.g. nylon or nitrocellulose) or a microsphere (bead) or a chip. Prior to application to the membrane or fixation it may be convenient to modify the

nucleic acid probe in order to facilitate fixation or improve the hybridization efficiency. Such modifications may encompass homopolymer tailing, coupling with different reactive groups such as aliphatic groups, NH<sub>2</sub> groups, SH groups, carboxylic groups, or coupling with biotin, haptens or proteins.

5       The term "labelled" refers to the use of labelled nucleic acids. Labelling may be carried out by the use of labelled nucleotides incorporated during the polymerase step of the amplification such as illustrated by Saiki *et al.* (1988) or Bej *et al.* (1990) or labelled primers, or by any other method known to the person skilled in the art. The nature of the label may be isotopic (<sup>32</sup>P, <sup>35</sup>S, etc.) or non-isotopic (biotin, digoxigenin, etc.).

10       The term "biological sample or sample" refers to for instance naso-pharyngeal aspirates, throat or nasopharyngeal swabs, nasopharyngeal washes or tracheal aspirates or other respiratory tract sample comprising DNA or RNA.

For designing probes with desired characteristics, the following useful guidelines known to the person skilled in the art can be applied.

15       Because the extent and specificity of hybridization reactions such as those described herein are affected by a number of factors, manipulation of one or more of those factors will determine the exact sensitivity and specificity of a particular probe, whether perfectly complementary to its target or not. The importance and effect of various assay conditions are explained further herein.

20       The stability of the [probe : target] nucleic acid hybrid should be chosen to be compatible with the assay conditions. This may be accomplished by avoiding long AT-rich sequences, by terminating the hybrids with G:C base pairs, and by designing the probe with an appropriate T<sub>m</sub>. The beginning and end points of the probe should be chosen so that the length and %GC result in a T<sub>m</sub> about 2-10°C higher than the temperature at which  
25       the final assay will be performed. The base composition of the probe is significant because G-C base pairs exhibit greater thermal stability as compared to A-T base pairs due to additional hydrogen bonding. Thus, hybridization involving complementary nucleic acids of higher G-C content will be more stable at higher temperatures.

30       Conditions such as ionic strength and incubation temperature under which a probe will be used should also be taken into account when designing a probe. It is known that the degree of hybridization will increase as the ionic strength of the reaction mixture increases, and that the thermal stability of the hybrids will increase with increasing ionic strength. On the other hand, chemical reagents, such as formamide, urea, DMSO and alcohols, which disrupt hydrogen bonds, will increase the stringency of hybridization. Destabilization of the  
35       hydrogen bonds by such reagents can greatly reduce the T<sub>m</sub>. In general, optimal hybridization for synthetic oligonucleotide probes of about 10-50 bases in length occurs

approximately 5°C below the melting temperature for a given duplex. Incubation at temperatures below the optimum may allow mismatched base sequences to hybridize and can therefore result in reduced specificity.

It is desirable to have probes which hybridize only under conditions of high stringency. Under high stringency conditions only highly complementary nucleic acid hybrids will form; hybrids without a sufficient degree of complementarity will not form. Accordingly, the stringency of the assay conditions determines the amount of complementarity needed between two nucleic acid strands forming a hybrid. The degree of stringency is chosen such as to maximize the difference in stability between the hybrid formed with the target and the non-target nucleic acid.

Regions in the target DNA or RNA which are known to form strong internal structures inhibitory to hybridization are less preferred. Likewise, probes with extensive self-complementarity should be avoided. As explained above, hybridization is the association of two single strands of complementary nucleic acids to form a hydrogen bonded double strand. It is implicit that if one of the two strands is wholly or partially involved in a hybrid that it will be less able to participate in formation of a new hybrid. There can be intramolecular and intermolecular hybrids formed within the molecules of one type of probe if there is sufficient self complementarity. Such structures can be avoided through careful probe design. By designing a probe so that a substantial portion of the sequence of interest is single stranded, the rate and extent of hybridization may be greatly increased. Computer programs are available to search for this type of interaction. However, in certain instances, it may not be possible to avoid this type of interaction.

Standard hybridization and wash conditions are disclosed in the Materials & Methods section of the Examples. Other conditions are for instance 3X SSC (Sodium Saline Citrate), 20% deionized FA (Formamide) at 50°C. Other solutions (SSPE (Sodium saline phosphate EDTA), TMAC (Tetramethyl ammonium Chloride), etc.) and temperatures can also be used provided that the specificity and sensitivity of the probes is maintained. When needed, slight modifications of the probes in length or in sequence have to be carried out to maintain the specificity and sensitivity required under the given circumstances.

The term "hybridization buffer" means a buffer allowing a hybridization reaction between the probes and the polynucleic acids present in the sample, or the amplified products, under the appropriate stringency conditions.

The term "wash solution" means a solution enabling washing of the hybrids formed under the appropriate stringency conditions.

The invention, now being generally described, will be more readily understood by reference to the following examples and figures, which are included merely for the

purposes of illustration of certain aspects and embodiments of the present invention and are in no way to be construed as limiting the present invention. All of the references mentioned herein are incorporated by reference.

**BRIEF DESCRIPTION OF THE FIGURES AND TABLES**

**Figure 1.** Separation of m-RT-PCR products on agarose Gel. 10 µl of m-RT-PCR products were separated on 2 % agarose gel. The m-RT-PCR was performed using 1 µl of viral or bacterial nucleic acid as template as described in material and methods. The expected product lengths are given in the text. DNA fragment size of marker (0.7 µg of MspI digested pUC19) in base pairs (bp) is 1: 501 bp; 2: 404 bp; 3: 331 bp; 4: 242 bp; 5: 190 bp; 6: 147 bp; 7: 110 bp.

**Figure 2.** Proportion of positive m-RT-PCR results. The number of positive m-RT-PCR results and total samples is given on the y-axis. The time scale on the x-axis is from November 1995 to April 1998.

**Figure 3.** Frequency of positive m-RT-PCR-ELISA results in clinical specimens. The number of positive m-RT-PCR results for each of the nine organisms is given on the y-axis. The time scale on the x-axis is from November 1995 to April 1998.

**Figure 4.** Percentage of organisms causing infections. The amount of organisms causing a respiratory disease is given in percent of the total of organisms causing the according disease. Organisms not included in the test are not shown in the figure.

**Figure 5** shows the separation on a 2% agarosegel of the amplicons obtained after multiplex-RT-PCR on reference material shows discrete bands of the expected size for all organisms tested.

**Figure 6** shows hybridization results of these amplicons with the LiPA strips as well as a negative control. These results clearly demonstrate that all the probes on the strip react specifically with their corresponding amplicons and no cross-hybridization is seen between the different organisms tested.

**Table 1** shows the results from a comparative study between m-RT-PCR-ELISA and commercial EIA's.

**Table 2** shows the primer sequences used in Example 1.

**Table 3** summarizes the different probes for the organisms identified as originally described and their adapted versions for LiPA use.

**Table 4** summarizes the sequences of the primers and probes, derived from the 16S-23S rRNA spacer region for the bacterial pathogens.

**Table 5** shows the sequences of probes for RSV used in Example 3.

**Table 6** shows a comparison of culture and LiPA results for a series of 36 blinded samples, performed in Example 3.

**Table 7.** shows a comparison of culture and LiPA results for a series of 30 blinded specimens for culture of *Mycoplasma pneumoniae* using multiplex-RT-PCR and LiPA, performed in Example 3.

## **EXAMPLES**

### **Example 1**

#### **Abbreviations.**

Acute respiratory tract infection (ARI); reverse transcription combined with PCR (RT-PCR); multiplex-RT-PCR (m-RT-PCR); m-RT-PCR combined with microwell hybridization assay (m-RT-PCR-ELISA); influenza virus type A (influenza A or InfA); Influenzavirus type B (influenza B or InfB); parainfluenzavirus type 1 (PIV-1); parainfluenzavirus type 3 (PIV-3); respiratory syncytial virus (RSV).

## **MATERIALS AND METHODS**

### **1. Patient samples**

Nasopharyngeal aspirates were obtained from children hospitalized with ARI at our institution in the time between November 1995 through April 1998. Diagnosis included pneumonia, wheezing bronchitis, bronchitis, laryngotracheitis (the latter encompassing laryngitis, laryngo-tracheo-bronchitis and (pseudo-) croup), pharyngitis, tonsillitis, rhinitis, conjunctivitis, otitis media and were obtained from the computer-based discharge-diagnosis database of the hospital. While specimen collection was not complete during the first winter season (November 1995 to April 1996), it was >95 % complete for the remaining time as October 1st, 1996. Specimens were collected the first working day following hospitalization, directly brought to the laboratory, initially stored at 4°C, prepared for testing and afterwards or for longer storage frozen at minus 70°C. Samples were split with appropriate precautions to avoid contamination and one portion was used directly for detection of RSV and influenza type A antigen by the use of enzyme immuno assays (EIA) (Becton Dickinson, Heidelberg, Germany). A second portion was used for m-RT-PCR followed by agarose gel electrophoresis and specification in a microwell hybridization assay.

### **2. Nucleic acid extraction**

Samples received from November 1995 through July 1997 were prepared as follows. Total nucleic acids were obtained from 100 µl of respiratory specimens diluted with 100 µl 0,9 % NaCl-solution. Sodiumdodecyl sulphate was added to a final concentration of 0,1 %. Nucleic acid extraction was accomplished once with 1 volume of 1:1 phenol-chloroform mixture and once with 1 volume chloroform and precipitated with 0,3 M ammonium acetate and ethanol. Nucleic acid pellets were dried and resuspended in 15 µl of



diethylpyrocarbonate-treated, bidistilled water. Specimens received from August 1997 to April 1998 were prepared using the Boehringer "High Pure Viral Nucleic Acid Kit" following the instructions of the purchaser (Boehringer Mannheim, Mannheim, Germany).

Controls of the preparation procedure were as follows: One negative sample (sputa from healthy persons) was included in each series of 5-10 samples to monitor for potential cross-contamination. In case of a false positive result in the negative control, the m-RT-PCR was repeated on all positive clinical samples in that series with another portion of the clinical specimen. Positive controls from culture (influenza A, influenza B, PIV-1, PIV-3 or RSV respectively) were used in each test to document the efficiency of the preparation procedure. Prepared samples were used immediately for m-RT-PCR and remaining aliquots were stored at minus 70°C.

### 3. Multiplex-RT-PCR

Target sequences were coding/non-coding regions, respectively, of: F1 subunit of the fusion glycoprotein gene for RSV, hemagglutininneuraminidase gene for PIV-1, 5' noncoding region of the PIV-3 fusion protein gene, nucleotide sequence of the 16S ribosomal RNA for *M. pneumoniae*, nucleotide sequence of the 16S ribosomal RNA for *C. pneumoniae*, nucleotide sequence of the 16S ribosomal RNA for *C. pneumoniae*, an among enteroviruses highly conserved 5' noncoding region for enterovirus, non-structural protein gene from influenza A and influenza B and sequence of the hexon gene for adenoviruses. Sequences were selected from procedures described previously (Paton *et al.*, 1992; Karron *et al.*, 1992; Fan and Henrickson, 1996; Rotbart, 1990; Gaydos *et al.*, 1992; Van Kuppeveld *et al.*, 1992; Claas *et al.*, 1992; Hierholzer *et al.* 1993). For adenovirus the sequence of probe A was used as second amplification primer instead of primer 2 (Hierholzer, 1993).

Five to six µl of the nucleic preparations from clinical specimens were included in the reverse transcription (RT) reaction in a final volume of 20 µl. The RT was performed for 60 min at 37°C with the following buffer composition: 50 mM Tris-HCl (pH 8.3), 75mM MgCl<sub>2</sub>, 10 mM (each) deoxynucleoside triphosphates (Pharmacia Biotech, Uppsala, Sweden), 0.2 µg/ul hexanucleotide mix (Boehringer Mannheim, Mannheim, Germany), 20 U RNAsin (Promega, Madison, Wisconsin USA) and 10 U of Moloney murine leukemia virus reverse transcriptase (Eurogentec, Seraing, Belgium).

After heat inactivation of reverse transcriptase at 90°C for 5 min, the entire 20-µl RT reaction mixture was used for multiplex PCR in a total volume of 80 µl. The buffer composition (without consideration of the RT-buffer) was 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1,5 mM MgCl<sub>2</sub>, 0.001 % gelatin, 0.2 mM dATP, dCTP, dGTP, 0.2 mM dTTP, 0.01 mM

digoxigenin-11-dUTP (Boehringer Mannheim, Mannheim, Germany), 1  $\mu$ M (each) primer (Eurogentec, Seraing, Belgium), and 5 U of AmpliTaq-Gold polymerase (Perkin-Elmer, Branchburg, NJ, USA). PCR was performed on a PE 9600 Thermocycler (Perkin, Elmer, Branchburg, NJ, USA) as follows: 40 cycles of denaturation at 94°C for 30 sec (10 min during cycle 1), annealing at 50°C for 30 sec and extension at 72°C for 30 sec (7 min during cycle 40).

As negative control bank reagent that contained H<sub>2</sub>O was used instead of nucleic acid. As positive m-RT-PCR control total cellular nucleic acid extracted from virus and/or bacterial stocks was used.

#### 4. Prevention of carry-over contamination

To prevent carry-over contamination within the laboratory, the following precautions were taken: All purchased reagents were split into small aliquots. The preparation of PCR reagents, the extraction of nucleic acids from clinical samples and the amplification step were conducted in three different rooms. Tips equipped with sealing filters (safeseal-tip from BIOzym, Hess. Oldendorf, Germany) were used for pipetting reagents introduced into the PCR and all areas and equipment were decontaminated with sodiumhypochlorite and Bacillol (an alcoholic disinfectant from: Bode Chemie, Hamburg, Germany) prior to and after pipetting.

#### 5. Agarose gel electrophoresis

Electrophoretic separation of PCR products (10  $\mu$ l) was performed for 30 minutes at 130 tot 160 mA on 2 % agarose gels in 0.5 x TBE buffer (0.045M Tris-borate, 0.001M EDTA), stained with ethidium bromide and PCR products were visualized by UV illumination as described by Sambrook et al. (Sambrook *et al.*, 1989). For control of fragment lengths, 0.6 - 0.8  $\mu$ g of *MspI* digested pUC19 DNA was applied as marker.

#### 6. Microwell hybridization analysis

This assay was performed using the PCR-ELISA system from Boehringer Mannheim (Mannheim, Germany). Nine wells of a streptavidin-coated microtiter plate were each filed with 5  $\mu$ l of PCR product and denatured by adding 25  $\mu$ l of 0.2 N NaOH to each well. After 5 minutes 200  $\mu$ l hybridization buffer containing 2 pmol of the respective biotinylated capture probe was added. The capture probes used were specific for the amplified target sequences (see above) and the sequences of the probes for enterovirus, influenza A, influenza B, PIV-1, adenovirus (probeB) and *M. pneumoniae* (Gpo1) were identical to previously reported sequences (Rotbart, 1990; Claas et al., 1992; Van Kuppenveld et al.,

1992; Hierholzer et al., 1993; Fan and Hendricksom, 1996). The sequences of probes used for the others are 5'-CCT GCA TTA ACA CTA AAT TC-3' (SEQ ID NO 1) for RSV; 5'-TCT TGC TAC CTT CTG TAC TAA-3' (SEQ ID NO 2) for *C. pneumonia* and 5'-AAA ATT CCA AAA GAG ACC GGC-3' (SEQ ID NO 4) for PIV-3. All capture probes were 3'-

5 biotinylated and purchased by Eurogentec (Seraing, Belgium), Capture was allowed to proceed for 1 h at 37°C, and afterwards the wells were washed four times with 200 µl of washing solution (Boehringer Mannheim, Mannheim, Germany) at room temperature. To each well 200 µl of anti-DIG-peroxidase (10 mU/ml, Boehringer Mannheim, Mannheim, Germany) diluted 1/1,000 in a buffer containing 100 mM Tris-HCl, 150 mM NaCl (pH 7.5)

10 was added. Plates were incubated for 30 min at 37°C and wells were washed four times with washing solution. 200 µl ABTS® substrate solution (Boehringer Mannheim, Mannheim, Germany) was added, and the wells were incubated for 30 min at 37°C. The optical density (OD) was read on a DIAS reader (Dynatech Laboratories, Guernsey, Channel Islands) at 405 nm (reference filter 492 nm). The run was considered valid, if all negative control

15 values were less than 0.2 OD units and the positive control was higher than 1.0 OD units. Samples were classified as PCR positive or negative according to a cut-off OD value of 0.5 and by comparison with the results from gel electrophoresis. Samples with initial readings of between 0.2 and 0.5 were considered borderline and were classified as positive or negative only after retesting with the specific single primer set. Positive hybridization

20 controls were included in each microwell hybridization assay. They consisted of PCR products derived from the positive controls that were included in the m-RT-PCR.

## 7. Administration of data

All data obtained were managed in a Microsoft Access database. This database

25 included all available information about patients as well as all diagnostic data and results from m-RT-PCR-ELISA, and in case of influenza A and RSV the data of the EIA.

## 8. Bacterial and viral stocks

Bacterial and viral stocks used as positive control were kindly provided by the

30 following persons: B. Schweiger and E. Schreier, (Robert-Koch-Institute, Berlin) enteroviruses, Influenza A and influenza B; K.M. Edwards (Vanderbilt University, Tennessee, USA) RSV, PIV-1, PIV-3; A. Strecker (Institute for Virology, Bochum) RSV-long, PIV-3; R. Krausse and P. Rautenberg (Institute for Medical Microbiology, Kiel), *M. pneumoniae*, *C. pneumoniae*, and adenoviruses.

35 The exact number of viruses or bacteria within these samples was not known and was assumed to be at most 10<sup>8</sup>/ml as stated by B. Schweiger and P. Rautenberg (personal

communication). For preliminary sensitivity testing of m-RT-PCR consecutive dilutions (tenfold steps) of prepared nucleic acids from these cultures were used as template for m-RT-PCR and for amplification with single primer sets.

Due to unavailable information about the exact number of viruses and bacteria the probable amount of nucleic acids which was sufficient to result in an amplification product was calculated based on the assumed particle number ( $10^8$ /ml undiluted sample). To detect possible cross reactivity among the organisms one  $\mu$ l of undiluted nucleic acid from each organism was used in an m-RT-PCR.

## RESULTS

### 1. Multiplex RT-PCR on bacterial and viral nucleic acids.

The m-RT-PCR-ELISA procedure was tested with nucleic acids prepared from the stock solutions as described in material and methods. As can be seen in figure 1 only one specific amplification product could be observed in each lane. The predicted sizes of the amplification products (*C. pneumoniae*, 463 bp; *M. pneumoniae*, 277 bp; influenza B, 249 bp; RSV, 239 bp; PIV-3, 205 bp; influenza A, 190 bp; PIV-1, 179 bp; enterovirus 154 bp; adenovirus, 134 bp) were in good agreement with the fragment sizes calculated from the agarose gel (Fig.1). This suggests that the m-RT-PCR yielded specific products. However, differentiation of influenza A and PIV-3 by fragment size in gel electrophoresis alone is difficult, but the absorbance values obtained by the PCR-ELISA test confirmed this specificity. Unconsumed primers are visible at the bottom of the gel.

In order to estimate the sensitivity of the m-RT-PCR concentrated virus stock solutions were diluted consecutively in 10-fold steps and tested with specific primer pairs to produce amplification products visible on agarose gel which were specified in the PCR-ELISA. Assuming that a maximum of  $10^8$  of the respective microorganisms per ml were present in the original stock solution, it was calculated that the method was able to detect 1 target sequence of *M. pneumoniae* and 1 target sequence of *C. pneumoniae*, 10 copies of adenovirus DNA and enterovirus RNA, 100 copies of PIV-1, PIV-3, influenza A, influenza B and RSV-RNA in the analogue m-RT-PCR reaction.

### 2. Comparison of Enzyme Immuno Assay (EIA) with m-RT-PCR-ELISA.

To receive information about the quality of the m-RT-PCR-ELISA we compared results obtained with those from commercial EIA's. With this EIA 940 clinical specimens were tested for the presence of influenza A and 1.031 clinical specimens for the presence of RSV. Results are summarized in table 1. The overall accordance was 95 % of PCR results for RSV to those obtained by EIA (with 140 positive + 891 negative specimens in

EIA as reference = 100 %). 25 specimens were identified as RSV positive by PCR-ELISA only, 24 as RSV positive by EIA only. In case of influenza A the overall accordance of PCR to EIA was 98 % (with 53 positive + 887 negative in EIA as reference = 100 %) with 1 specimen positive by EIA only and 14 specimens positive by PCR ELISA only.

5

### 3. Results of m-RT-PCR-ELISA with clinical specimens.

A total of 1.118 samples were tested by m-RT-PCR-ELISA. The number of samples tested over time and the proportion of positive PCR results can be taken from figure 2. The amount of specimens increased periodically during all cold seasons (from November to April) and this correlated with an increased number of positive PCR results. During the winter season 1996/1997 the maximum number of patients samples (n=106) was received in February and detection of at least one microorganism by m-RT-PCR was accomplished in 48 %. The lower number of specimens in the winter 1995/1996 was due to incomplete sample collection early during our test series. Results for the different microorganisms are shown in detail in figure 3. A total of 723 (65%) specimens were negative and 395 (35 %) were positive for at least one of the organisms included in the test. Of the isolates 37.5 % were RSV, 20.0 % influenza A, 12.9 % adenoviruses, 10.6 % enteroviruses, 8.1 % *M. pneumoniae*, 4.3 % PIV-3, 3.5 % PIV-1, 2.8 % influenza B and 0.2 % *C. pneumoniae*, (based on total positive m-RT-PCR-ELISA). RSV and influenza A mainly were detected from December to May. For influenza B (February to April 1997) and for PIV-1 (September to December 1997) only one main peak was observed. Infection with adenovirus, enterovirus, PIV-3 and *M. pneumoniae* was detected more or less constantly over the time. *C. pneumoniae* was detected only once in January 1997.

### 4. Simultaneous detection of two organisms.

The m-RT-PCR revealed evidence of simultaneous infection with two organisms in 20 cases (1.8 % of the total or 5 % of the positive specimens). Co-amplification of adenovirus nucleic acid sequence occurred with *C. pneumoniae* (1x), enterovirus (1x), influenza A (1x) and RSV (5x). Dual infections involving enteroviruses were detected with adenovirus (1x), influenza A (3x), influenza B (1x), PIV-3 (3x), *M. pneumoniae* (1x) and with RSV (3x).

Furthermore influenza B nucleic acid was co-amplified with RSV and *M. pneumoniae* with PIV-1 each in one specimen.

35

## 5. Clinical data.

Clinical data were available as of February 1995 from 861/1.061 sample -patient pairs with second or following samples from the same hospital admission of one patient being excluded. From these 861 patients, 550 were between 0 to 2 years of age, 153 were between 2 to 5 years of age and 158 were older than 5 years. In 62 % of those specimens no bacterial or viral nucleic acids could be detected by m-RT-PCR. The most frequent diagnosis in this hospital-based study was pneumoniae (309 cases or 36 %). It was most commonly caused by RSV (n=59), influenza A (n=17), *M. pneumoniae* (n=16) and adenovirus (n=15). Enterovirus, PIV-3, PIV-1 and influenza B were associated with less than 10 pneumonia cases each. Among 167 patients with wheezing bronchitis (19 % of 861 specimens) RSV was detected in 45 cases, adenovirus in 16 and enterovirus, influenza A, influenza B, PIV-1, PIV-3 and *M. pneumoniae* in less than 10 cases each. Bronchitis was observed in a total of 95 patients (11 % of the 861 specimens) and the detected organisms were RSV (13 cases), enterovirus and influenza A (4 cases each), adenovirus (3 cases). Rhinitis was diagnosed in 7.1 %, laryngotracheitis in 6.2 %, and pharyngitis, otitis media, tonsillitis and conjunctivitis in less than 5 % each of the 861 specimens tested with the detection of a microorganism by m-RT-PCR in less than 10 cases. Other diseases were diagnosed in 9.1 % of the patients.

The frequency of detection of one of the nine organisms in the PCR for a given respiratory disease is shown in figure 4. RSV was most commonly associated with pneumonia, wheezing bronchitis, bronchitis, otitis media or pharyngitis. Influenza A was associated with more than 5 % of the cases of otitis media, tonsillitis, pharyngitis, laryngotracheitis, pneumonia; enteroviruses were associated with more than 5 % of cases of tonsillitis, pharyngitis; adenoviruses were associated with pharyngitis, wheezing bronchitis, conjunctivitis and tonsillitis; *M. pneumoniae* most commonly associated with pneumoniae, while PIV-1 was mainly associated with laryngotracheitis and PIV-3 with laryngotracheitis and conjunctivitis. *C. pneumoniae* was detected only once in a patient with bronchitis.

### Example 2 : LiPA application for acute respiratory tract infections

#### 1. Design of oligonucleotide probes for LiPA application

Some of the oligonucleotide probes used in Example 1 were adapted in order to obtain good specificities and sensitivities for the different organisms when used in a LiPA

assay (Line Probe Assay, WO 94/12670). Table 3 summarizes the different probes for the organisms identified as originally described and their adapted versions for LiPA use.

Optimized probes were provided enzymatically with a poly-T-tail using terminal deoxynucleotidyl transferase (Pharmacia) in a standard reaction buffer. After one hour incubation, the reaction was stopped and the tailed probes were precipitated and washed with ice-cold ethanol. Probes were dissolved in 6x SSC at their respectively specific concentrations and applied as horizontal lines on membrane strips. Biotinylated DNA was applied alongside as positive control. The oligonucleotides were fixed to the membrane by baking at 80°C for 12 hours. The membrane was then sliced into 4mm strips.

## 2. Nucleic acid preparation and PCR amplification

Bacterial and viral culture stocks were used as reference material. Nucleic acid was extracted according to standard procedures as described above.

One to five µl of the nucleic acid preparation was used in the multiplex-RT-PCR as described previously, with the exception that the cycle number was reduced to 35 and labelling of the amplicons was done by using biotinylated primers instead of the incorporation of digoxigenin-11-dUTP.

## 3. LiPA test performance

Equal volumes (5 to 10 µl) of the biotinylated PCR fragments and of the denaturation solution (400 mM NaOH/10 mM EDTA) were mixed in test troughs and incubated at room temperature for 5 min. Then, 2 ml of the 50°C prewarmed hybridization solution (2xSSC/0.1% SDS) was added followed by the addition of one strip per test trough. Hybridization occurred for 1 hour at 50°C in a closed shaking water bath. The strips were washed twice with 2 ml of stringent wash solution (2xSSC/0.1% SDS) at room temperature for 20 sec, and once at 50°C for 15 min. Following this stringent wash, strips were rinsed two times with 2 ml of the Innogenetics standard Rinse Solution (RS). Strips were incubated on a rotating platform with the alkaline phosphatase-labelled streptavidin conjugate, diluted in standard Conjugate Solution for 3 min at room temperature. Strips were then washed twice with 2 ml of RS and once with standard Substrate Buffer (SB), and the colour reaction was started by adding BCIP and NBT to the SB. After 30 min at room temperature, the colour reaction was stopped by replacing the colour compounds by distilled water. Immediately after drying, the strips were interpreted. The complete procedure described above can also be replaced by the standard Inno-LiPA automation device (Auto-LiPA, Innogenetics, Zwijnaarde, Belgium).

As can be seen in Figure 5, the separation on a 2% agarose gel of the amplicons obtained after multiplex-RT-PCR on reference material shows discrete bands of the expected size for all organisms tested.

Figure 6 shows hybridization results of these amplicons with the LiPA strips as well as a negative control. These results clearly demonstrate that all the probes on the strip react specifically with their corresponding amplicons and no cross-hybridization is seen between the different organisms tested.

#### 4. New probe development for *C. pneumoniae*, *M. pneumoniae*, *B. pertussis* and *B. parapertussis*.

To replace primers and probes (16S rRNA) used in the multiplex-RT-PCR for detection of *M. pneumoniae* and *C. pneumoniae*, a new set of primers and probes was developed for these organisms derived from the 16S-23S rRNA spacer region. Also primers and probes were developed for the specific detection of *B. pertussis* and *B. parapertussis* or *B. bronchiseptica* to add to the multiplex-RT-PCR.

In Table 4, the sequences of the primers and probes, derived from the 16S-23S rRNA spacer region for these bacterial pathogens are summarized.

PCR experiments demonstrated that all selected primersets specifically amplified the corresponding organisms and no amplicons were obtained using nucleic acids derived from phylogenetically related organisms or any of the other infectious agents detected in the multiplex-RT-PCR.

Biotinylated universal primers derived from the 3' end of the 16S rRNA and the 5' part of the 23S rRNA were used to amplify the 16S-23S rRNA spacer region of the bacteria of interest and their closest relatives.

Reverse hybridization on LiPA strips in 2x SSC/0.1% SDS at 50°C showed that all selected probes specifically reacted with the organisms of interest and no cross-reaction was seen with amplicons derived from the previously described multiplex-RT-PCR.

Initial experiments demonstrated that primers and probes (derived from the ribosomal spacer) can be implemented in the multiplex-RT-PCR to replace the currently used primers and probes for *M. pneumoniae* and *C. pneumoniae* and that the assay can be extended by adding primers and probes for *Bordetella* spp. involved in respiratory tract infections.

From these results it is anticipated that this set can be further extended with probes (more particularly from the 16S-23S rRNA spacer region) for other relevant pathogens such as *Legionella pneumophila*.



**Example 3: m-RT-PCR and LiPA hybridization on culture supernatants**

To check the accuracy and specificity of the multiplex-RT-PCR and LiPA hybridization, a number of blinded cultures were analyzed with the LiPA assay.

5

**1. Sample preparation and PCR**

Nucleic acid preparation was done on culture supernatants using the Boehringer-Mannheim "High Pure Viral Nucleic Acid Kit" as described by the manufacturer. The m-RT-PCR involved the reverse transcription of the RNA from RNA organisms (RSV, PIV1, PIV3, InfA, InfB, enterovirus) followed by a PCR amplification of the corresponding cDNA and the DNA of adenovirus, *M. pneumoniae*, *C. pneumoniae*, *B. pertussis* and *B. parapertussis* as being described in the previous examples.

Primers were chosen from previously published highly conserved target sequences, except for amplification of the bacterial species, primers used are the following : for *M. pneumoniae* SEQ ID NO 17 and SEQ ID NO 19; for *C. pneumoniae* SEQ ID NO 20 and SEQ ID NO 21 and for both Bordetella species SEQ ID NO 22 and SEQ ID NO 23.

15

**2. LiPA hybridization**

Five to 10 µl of PCR product was hybridized to LiPA strips containing specific probes for the different organisms, as described in Table 3 for enterovirus, influenza A and B, adenovirus and parainfluenzavirus, and in Table 4 for the bacterial species. For RSV, the probes used are as described in Table 5.

20

Hybridization was done as described in example 2.

25

**3. Results**

A comparison of culture and LiPA results for a first series of 36 blinded samples is summarized in Table 6.

LiPA results are concordant with culture results in most of the cases. In two cases, multiplex testing revealed the presence of double infections, where culture results only detected one of the two organisms present.

30

Negative LiPA results obtained were seen with old culture supernatants, possibly due to degradation of nucleic acid material.

In a second experiment, blinded samples for culture of *Mycoplasma pneumoniae* were evaluated using the multiplex-RT-PCR and subsequent LiPA hybridization. Results of 30 blinded specimens are summarized Table 7.

35

The results in the LiPA testing were 100% concordant to the results obtained in culture.

**Table 1: Comparison of EIA and m-RT-PCR-ELISA**

<i><b>RSV</b></i>	<b>EIA</b>		
		Pos.	Neg.
<b>PCR</b>	Pos.	116	25
	Neg.	24	866
	<b>Total</b>	140	891

<i><b>InfA</b></i>	<b>EIA</b>		
		Pos.	Neg.
<b>PCR</b>	Pos.	52	14
	Neg.	1	873
	<b>Total</b>	53	887

**Table 2. Primer sequences used in Example 1**

ENTERO- FP1: att gtc acc ata agc agc ca-3'

ENTERO- RP1: tcc tcc ggc ccc tga atg cg-3'

MPN-FP1: aag gac ctg caa ggg ttc gt-3'

MPN-RP1: ctc tag cca tta cct gct aa-3'

INFLUA-FP1: aag ggc ttt cac cga aga gg-3'

INFLUA-RP1: ccc att ctc att act gct tc-3'

INFLUB-FP1: atg gcc atc gga tcc tca ac-3'

INFLUB-RP1: tgt cag cta tta tgg agc tg-3'

ADENO-FP1: gcc gag aag ggc gtg cgc agg ta-3'

ADENO-RP1: atg act ttt gag gtg gat ccc atg ga-3'

CPN-FP1: tga caa ctg tag aaa tac agc-3'

CPN-RP1: cgc ctc tct cct ata aat-3'

PIV1-FP1: cac atc ctt gag tga tta agt ttg atg a-3'

PIV1-RP1: att tct gga gat gtc ccg tag gag aac-3'

PIV3-FP1: tag cag tat tga agt tgg ca-3'

PIV3-RP1: aga ggt caa tac caa caa cta-3'

RSV-FP1: tgt tat agg cat atc att ga-3'

RSV-RP1: tta acc agc aaa gtg tta ga-3'

**Table 3.**

Organism	Original probe	Adapted versions*	Name**
Enterovirus	gaaacacggacacccaaagta	gaaacacggacacccaaagta (SEQ ID NO 4)	<b>entero1</b>
Influenza A	gtcctcatcggaggacttgaaatgat	catcggaggactgaatgg (SEQ ID NO 5)	<b>influa1</b>
Influenza B	gtcaagagcaccgattatcac	gtcaagagcaccgattatcac (SEQ ID NO 6)	<b>influb1</b>
Adenovirus	ctcgatgacgcgcgggtgc	gatgacgcgcgggtg (SEQ ID NO 7)	<b>adeno1</b>
		tctcgatgacgcgcgcg (SEQ ID NO 8)	<b>adeno2</b>
		cataaagaagggtgggc (SEQ ID NO 9)	<b>adeno3</b>
Parainfluenza 1	taccttcattatcaattgtaagtc	ccttcattatcaattgtaagtc (SEQ ID NO 10)	<b>piv11</b>
		ccttcattatcaattggtgatgc (SEQ ID NO 11)	<b>piv12</b>
		gttagaytaccttcattatcaattggt (SEQ ID NO 12)	<b>piv13</b>
Parainfluenza 3	aaaattccaagagagaccggc	aaaattccaagagagaccggc (SEQ ID NO 13)	<b>piv31</b>
RSV	cctgcattaacactaaattc	cacctgcattaacactaaattct (SEQ ID NO 14)	<b>rsv1</b>
<i>M. pneumoniae</i>	actctacggaggcagcagta	ctacggaggcagcagcagc (SEQ ID NO 15)	<b>mpn1</b>
<i>C. pneumoniae</i>	tcttgctaccttctgtactaa	tcttgctaccttctgtactaa (SEQ ID NO 16)	<b>cpn1</b>

\* y = c or t

\*\* Probes in bold were used on first generation LIPA assay.

**Table 4.** Sequences of the primers and probes, derived from the 16S-23S rRNA spacer region.

Organism	Primers*	Probes
Mycoplasma pneumoniae	FP1: ggtagatcacctcttctaaag (SEQ ID NO 17) FP2: gtgtaataaataaaccaaatcc (SEQ ID NO 18) RP: gcatcaccataagcccttag (SEQ ID NO 19)	MPN3: ggtaaataaacccaaatccct (SEQ ID NO 24) MPN4: gaacattccgctcttctc (SEQ ID NO 25) MPN5: gaacattccgctcttctcaa (SEQ ID NO 26)
Chlamydia pneumoniae	FP: ccttttaaggacaaaggaaggtag (SEQ ID NO 20) RP: gatcatgcaagttacttcacc (SEQ ID NO 21)	CPN2: gcaagtattttatattccgcatt (SEQ ID NO 27) CPN3: gtttcaaaacattcagtatatgac (SEQ ID NO 28)
Bordetella pertussis	FP: tatagctgtggatcggtgg (SEQ ID NO 22) RP: ccaaaaccaacgcttaacac (SEQ ID NO 23)	BP2: gcctgtccagaggatg (SEQ ID NO 29) BPP1: cccgtctgaagatggg (SEQ ID NO 30)
Bordetella parapertussis/bronchiseptica	idem B. pertussis	

\* : FP = forward primer; RP = reverse primer.

**Table 5.** Sequences of probes for RSV, used in example 3.

Probe*	Name
tta aca trt aag tgc tta mag (SEQ ID NO 31)	rsv2
cct gca ttr aca cta aat tc (SEQ ID NO 32)	rsv6
cac ctg cat tra cac taa att c (SEQ ID NO 33)	rsv7
ott aca cct gca ttr aca cta aat tc (SEQ ID NO 34)	rsv8

\* r = a or g, and m = a or c

5

**Table 6.** Culture and LiPA results for a series of 36 blinded samples

Specimen	Culture-result	LiPA-result
1	Adenovirus	Adenovirus
2	Adenovirus 4	Adenovirus
3	Adenovirus 4	Adenovirus
4	Adenovirus	Enterovirus + Adenovirus
5	Adenovirus	Adenovirus
6	Echo Type 24 12374/97	Enterovirus
7	Echo Type 30 7682/97	Enterovirus
8	Inf A/WSN (H1N1) HA:1:1024	Influenza A
9	Inf A/Hongkong HA:1:128	Influenza A
10	Inf A/Shope/54 HA:1:256	Influenza A
11	Inf B/Hongkong HA:1:64	Influenza A + Influenza B
12	Inf B/Lee/40 HA:1:64	Influenza B
13	Inf B/Beijing/6 HA:1:64	Influenza B
14	Inf B/Victoria HA:1:64	Influenza B
15	Inf A/Wuhan/371/95 HA:1:32	Influenza A
16	Inf A/Texas/36/91 HA:1:256	Influenza A
17	Inf A/JHB/33/94 HA:1:256	negative
18	Inf B/Harbin/7/94 HA:1:32	Influenza B

19	Inf A/Nanchang/93/95 HA:1:64	Influenza A
20	Inf B/Singapour/6/86 HA:1:256	Influenza B
21	PIV 2	negative
22	PIV 2	negative
23	PIV 2	negative
24	serological Inf A positive	negative
25	serological Inf A positive	negative
26	Coxsackie Type B1	Enterovirus
27	Coxsackie Type B2	Enterovirus
28	Coxsackie Type B3	Enterovirus
29	Coxsackie Type B4	Enterovirus
30	Coxsackie Type B5	Enterovirus
31	Coxsackie Type B6	Enterovirus
32	Coxsackie Type A16	Enterovirus
33	Echo Type 6	Enterovirus
34	Echo Type 7	Enterovirus
35	Echo Type 11	Enterovirus
36	Echo Type 30 7682/97	Enterovirus

**Table 7.** Results of 30 blinded specimens for culture of *Mycoplasma pneumoniae*.

5

<i>M. pneumoniae</i>	LiPA positive	LiPA negative
Culture positive	17	0
Culture negative	0	13

## REFERENCES

- Adcock, P.M., G.G. Stout, M. A. Hauck, and G.S. Marshall (1997). Effect of rapid viral diagnosis on the management of children hospitalized with lower respiratory tract infection. *J. Pediatric. Infect. Dis.* **16**: 842-846.
- Asseline U., Delarue M., Lancelot G., Toulme F. and Thuong N. (1984) Nucleic acid-binding molecules with high affinity and base sequence specificity : intercalating agents covalently linked to oligodeoxynucleotides. *Proc. Natl. Acad. Sci. USA* **81**(11):3297-301.
- Bartlett, J.G., and L.M. Mundy (1995). Community-acquired pneumonia, *NEJM*, **333**: 1618 - 1624.
- Bej A., Mahbubani M., Miller R., Di Cesare J., Haff L., Atlas R. (1990) Multiplex PCR amplification and immobilized capture probes for detection of bacterial pathogens and indicators in water. *Mol Cell Probes* **4**:353-365.
- Claas, E.C.J., M.J.W. Sprenger, G.E.M. Kleter, R. van Beek, W.G.V. Quint, and N. Masurel (1992). Type-specific identification of influenza viruses A, B and C by the polymerase chain reaction. *J. Virol. Meth.* **39**: 1 - 13.
- Compton J. (1991) Nucleic acid sequence-based amplification. *Nature* **350**: 91-92.
- Dixon, R.E. (1985). Economic costs of respiratory infections in the United States. *Am. J. Med.* **78** (Suppl. 6B) : 45 - 51.
- Drews, A. L., R. L. Atmar, W.P. Glezen, B.D. Baxter, P.A. Piedra, S.B. Greenberg (1997). Dual respiratory virus infections. *Clin. Infect. Dis.* **25**: 1421 - 1429.
- Duck P. (1990) Probe amplifier system based on chimeric cycling oligonucleotides. *Biotechniques* **9**: 142-147.
- Echeviarra, J.E., D.D. Erdman, E.M. Swierkosz, B.P. Holloway, L.J. Anderson (1998). Simultaneous detection and identification of human parainfluenza viruses 1, 2, and 3 from clinical samples by multiplex PCR. *J. Clin. Microbiol.* **36**: 1388 - 1391.

Ellis, J.S., D.M. Fleming and M.C. Zambon (1997). Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. *J. Clin. Microbiol.* **35**: 2076 - 2082.

5 Falck G., J. Gnärpe, and H. Gnärpe (1997). Prevalence of Chlamydia pneumoniae in healthy children and in children with respiratory tract infections. *Pediatr. Infect. Dis. J.* **16**: 549 - 554.

10 Fan, J. And K. Henrickson (1996). Rapid diagnosis of human parainfluenza virus type 1 infection by quantitative reverse transcription-CPR-enzyme hybridization assay. *J. Clin. Microbiol.* **34** : 1914 - 1917.

15 Garenne, M., C. Ronsmans, H. Campbell (1992). The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. *World Health Stat. Q.* **45**: 180 - 191.

Gaydos, C.A., T.C. Quinn, and J.J. Eiden (1992). Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene. *J. Clin. Microbiol.* **30**: 796 - 800.

20 Gendrel, D., J. Raymond, F. Moulin, J.L. Iniguez, S. Ravilly, F. Habib, P. Lebon, and G. Kalifa (1997). Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. *Eur. J. Clin. Microbiol. Infect. Dis.* **16**: 388 - 391.

25 Gilbert, L.L., A. Dakhama, B.M. Bone, E.E. Thomas, and R.G. Hegele (1996). Diagnosis of viral respiratory tract infections in children by using a reverse transcription-PCR panel, *J. Clin. Microbiol.* **34**: 140 - 143.

30 Goo, Y.A.M.K. Hori, J.H. Jr. Voorhies, C.C. Kuo, S.P. Wang, L.A. Campbell (1995). Failure to detect Chlamydia pneumoniae in ear fluids from children with otitis media. *Pediatr. Infect. Dis. J.* **14**: 1000 - 1001.

Guatelli J., Whitfield K., Kwok D., Barringer K., Richman D. and Gengeras T. (1990) Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. *Proc. Natl. Acad. Sci. USA* **87**: 1874-1878.



Hassan-King, M., I. Baldeh, R. Adegbola, C. Omosigbo, S.O. Usen, A. Oparaugo, B.M. Greenwood (1996). Detection of Haemophilus influenzae and Streptococcus pneumoniae DNA in blood culture by a single PCR assay. *J. Clin. Microbiol.* **34**: 2030 - 2032.

5

Hassan-King, M., R. Adegbola, I. Baldeh, K. Mulholland, C. Omosigbo, A. Oparaugo, S. Usen, A. Palmer, G. Schneider, O. Secka, M. Weber, B. Greenwood (1998). A polymerase chain reaction for the diagnosis of Haemophilus influenzae type b disease in children and its evaluation during a vaccine trial. *Pediatr. Infect. Dis. J.* **17**: 309 - 312.

10

Hemming, V. G. (1994). Viral respiratory diseases in children : classification etiology, epidemiology and risk factors. *J. Pediatr.* **124**: S 13 - 16.

15

Hierholzer, J.C., P.E. Halonen, P.O. Dahlen, P. G Bingham, M.M. McDonough (1993). Detection of adenovirus in clinical specimens by polymerase chain reaction and liquid-phase hybridization quantitated by time-resolved fluoremetry, *J. Clin. Microbiol.* **31**: 1886 - 1891.

20

Hinman, A.R. (1998). Global progress in infectious diseases control. *Vaccine* **16**: 1116 - 1121.

25

Karron, R.A., K.L. O'Brien, J.L. Froehlich, and V.A. Brown (1992). Molecular epidemiology of a parainfluenza type 3 virus outbreak on a pediatric ward. *J. Inf. Dis.* **167**: 1441 - 1445.

30

Kawasaki, E.S. (1990). Amplification of RNA. P 21-27 In M.A. Innis, D.H. Gelfand, J.J. Sninsky and T.J. White (ed.), PCR protocols : A guide to methods and applications. Academic Press.

Kwoh D., Davis G., Whitfield K., Chappelle H., Dimichele L. and Gingeras T. (1989). Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format. *Proc Natl Acad Sci USA* **86**: 1173-1177.

Kwok S., Kellogg D., McKinney N., Spasic D., Goda L., Levenson C. and Sinisky J. (1990) Effects of primer-template mismatches on the polymerase chain reaction: Human immunodeficiency virus type 1 model studies. *Nucl. Acids Res.* **18**: 999.

5 Landgren U., Kaiser R., Sanders J. and Hood L. (1988) A ligase-mediated gene detection technique. *Science* **241**:1077-1080.

Lockhart, D.J., Dong, H., Byrne, M.C., Follettie, M., Gallo, M.V., Chee, M.S., Mittenman, M., Wang, C., Kobayashi, M., Horton, H. and Bown, E.L. (1996). Expression  
10 monitoring by hybridisation to high density oligonucleotide arrays. *Nature Biotechnology* **14**: 1675-1680.

Lomeli H., Tyagi S., Pritchard C., Lisardi P. and Kramer F. (1989) Quantitative  
15 assays based on the use of replicatable hybridization probes. *Clin Chem* **35**: 1826-1831.

Marx, A., T.J. Török, R.C. Holman, M.J. Clarke, and L.J. Anderson (1997). Pediatric  
Hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with  
human parainfluenzavirus 1 epidemics. *J. Infect. Dis.* **176** : 1423 - 1427.

20 Matsukura M., Shinozuka K., Zon G., Mitsuya H., Reitz M., Cohen J. and Broder S (1987). Phosphorothioate analogs of oligodeoxynucleotides : inhibitors of replication and cytopathic effects of human immunodeficiency virus. *Proc. Natl. Acad. Sci. USA* **84** (21):7706-10.

25 Messmer, T.O., K. Skelton, J. F. Moroney, H. Daugharty, and B.S. Fields (1997). Application of a nested, multiplex PCR to psittacosis outbreaks. *J. Clin. Microbiol.* **35**: 2043 - 2046.

30 Miller P, Yano J, Yano E, Carroll C, Jayaram K, Ts'o P (1979) Nonionic nucleic acid analogues. Synthesis and characterization of dideoxyribonucleoside methylphosphonates. *Biochemistry* **18** (23): 5134-43.

Mullis K., Faloona F., Scharf S. *et al.* Specific enzymatic amplification of DNA in vitro: the polymerase chain reaction (1986). *Gold Spring Harb. Symp. Quant. Biol.* **1**: 263-273.

35

Mullis K.B. and Faloona F.A. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction (1987). *Methods Enzymol.* **155**: 335-350.

5 Nielsen P., Egholm M., Berg R. and Buchardt O. (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. *Science* **254** (5037): 1497-500.

10 Nielsen P., Egholm M., Berg R. and Buchardt O. (1993) Sequence specific inhibition of DNA restriction enzyme cleavage by PNA. *Nucl. Acids Res.* **21**(2): 197-200.

Nohynek, H., J. Eskola, M. Kleemola, E. Jalonen, P. Saikku, M. Leinonen (1995). Bacterial antibody assays in the diagnosis of acute lower respiratory tract infection in children. *Pediatr. Infect. Dis. J.* **14**: 478 - 484.

15 Paton, A.W., J.C. Paton, A.J. Lawrence, P.N. Goldwater, and R.J. Harris (1992). Rapid detection of respiratory syncytial virus in nasopharyngeal aspirates by reverse transcription and polymerase chain reaction amplification. *J. Clin. Microbiol.* **30**: 901 - 904.

20 Reznikov, M., T.K. Blackmore, J.J. Finlay-Jones and D.L. Gordon (1995). Comparison of nasopharyngeal and throat swab specimens in a polymerase chain reaction-based test for *Mycoplasma pneumoniae*. *Eur. J. Clin. Microbiol. Infect. Dis.* **14**: 58 - 61.

25 Rotbart, H.A. (1990). Enzymatic RNA amplification of the enteroviruses. *J. Clin. Microbiol.* **28** : 438 - 442.

Rotbart, H.A., M.H. Sawyer, S. Fast, C. Lewinski, N. Murphy, E.F. Keyser, J. Spadaro, S.Y. Kao, M. Loeffelholz (1994). Diagnosis of enteroviral meningitis by using PCR with a colorimetric microwell detection assay. *J. Clin. Microbiol.* **32**: 2590 - 2592.

30 Saiki R.K., Bugawan T.L., Horn G.T. *et al.* Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes (1986). *Nature* **324**: 163-166.

Saiki, R.K., D.H. Gelfand, S. Stoffel, S.J. Scharf, R. Higuchi, G.T. Horn, K.B. Mullis, H.A. Erlich (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Science* **239**: 487 - 491.

- 5        Saiki R.K., Walsh P.S., Levenson, C.H. and Erlich H.A. Genetic analysis of amplified DNA with immobilizes sequence-specific oligonucleotide probes (1989). *Proc. Natl. Acad. Sci. USA* **86**: 6230-6234.

- 10        Saiki, R.K. (1990). Amplification of genomic DNA, p 13-20. In M.A. Innis, D.H. Gelfand, J.J. Sninsky and T.J. White (ed.) PCR protocols : A guide to methods and applications. Academic Press.

Saikku, P. (1997). Atypical respiratory pathogens. *Clin. Microbiol. Inf.* **3**: 599 - 604.

- 15        Sambrook, J., E.F. Fritsch, And T. Maniatis (1989). Molecular cloning : A Laboratory Manual. Cold Spring Harbor Laboratory. Cold Spring Harbor, NY.

- 20        Stauffer, F., H. Haber, A. Rieger, R. Mutschlechner, P. Hasenberger, V.J. Tevere, K.K. Young (1998). Genus level identification of mycobacteria from clinical specimens by using an easy-to-handle Mycobacterium-specific PCR Assay. *J. Clin. Microbiol.* **36**: 614 - 617.

Stuyver L., Rossau R., Wyseur A .et al (1993) Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. *J. Gen. Virol.* **74**: 1093-1102

- 25        Trolfors, B. And B.A. Claesson (1997). Childhood pneumonia : possibilities for aetiological diagnosis. *Baillière's Clinical Paediatrics.* **5**: 71 - 84.

UNICEF. (1993). Pneumonia, 3.5 millions deaths, The State of the World's Children.

- 30        Valassina, M. A.M. Cuppone, M.G. Cusi, P.E. Valensin (1997). Rapid detection of different RNA respiratory virus species by multiplex RT-PCR: application to clinical specimens. *Clin. Diagn. Virol.* **8**: 227 - 232.

- 35        Van Kuppeveld, F.J.M. van der Logt, A.F. Angulo, M.J. Van Zoest, W.G.V. Quint, H.G.M. Niesters, J.M.D. Galama, and W.J.G. Melchers (1992). Genus- and species-

specific identification of mycoplasmas by 16S rRNA amplification. *Appl. Env. Microbiol.* **58**: 2606 - 2615.

5       Woo, P.C., S.S. Chlu, W. H. Seto, M. Pelris (1997). Cost-effectiveness of rapid  
diagnosis of viral respiratory tract infections in pediatric patients. *J. Clin. Microbiol.* **35**: 1579  
- 1581.

10       Wu D. and Wallace B. (1989) The ligation amplification reaction (LAR) - amplification  
of specific DNA sequences using sequential rounds of template-dependent ligation.  
*Genomics* **4**:560-569.

Yang S.Y. A standardised method for detection of HLA-A and HLA-B alleles by one-  
dimensional isoelectric focusing (IEF) gel electrophoresis. *Immunobiology of HLA.*  
*Histocompatibility testing 1987* (ed. B. Dupont). Springer-Verlag, New York, pp. 332-335.

**CLAIMS**

1. Method for the detection of acute respiratory tract infection comprising the simultaneous amplification of several target nucleotide sequences present in a biological sample by means of a primer mixture comprising at least one primer set from each one of the following gene regions:

- the F1 subunit of the fusion glycoprotein gene for RSV,
- the hemagglutininneuraminidase gene for PIV-1,
- the 5' noncoding region of the PIV-3 fusion protein gene,
- 16 S rRNA sequence for *M. pneumoniae*,
- 16S rRNA sequence for *C. pneumoniae*,
- the 5' noncoding region for enterovirus,
- the non-structural protein gene from influenza A,
- the non-structural protein gene from influenza B, and,
- the hexon gene for adenoviruses.

2. Method according to claim 1 wherein said 16S rRNA primers are replaced by primers from the spacer region between the 16S and the 23S rRNA sequences.

3. Method according to claim 1 or 2 wherein in addition also at least one primer pair for the specific detection of *B. pertussis* and *B. parapertussis* are used.

4. Method according to any of claims 1 to 3 wherein said primers are chosen from Table 2 or Table 4.

5. Method according to any of claims 1 to 4 wherein said amplified products are subsequently detected using a probe, with said probe being preferably selected from Table 3, Table 4 or Table 5.

6. Primer chosen from SEQ ID NOs 17, 18, 19, 20, 21, 22 and 23.

7. Probe chosen from SEQ ID NOs 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33 and 34.

8. Kit for the detection of acute respiratory tract infection comprising a set of primers for performing a method according to any of claims 1 to 4.

9. Kit for the detection of acute respiratory tract infection comprising a set of probes for performing a method according to claim 5.

5        10. Kit according to claim 9, wherein said probes are applied as parallel lines on a solid support, preferably on a nylon membrane.

11. Kit for the detection of acute respiratory tract infection comprising at least one primer according to claim 6.

10

12. Kit for the detection of acute respiratory tract infection comprising at least one probe according to claim 7.




FIG. 1






FIG. 2

3/5




FIG. 3

4/5




FIG. 4




FIG. 5




FIG. 6

**RULE 63 (37 C.F.R. 1.63)**  
**INVENTORS DECLARATION FOR PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE RESPIRATORY TRACT INFECTIONS (ARI)**

the specification of which (check applicable box(es)):

- ☐ is attached hereto  
☐ was filed on

as U.S. Application Serial No.

(Atty Dkt. No. 2752-33)

☒ was filed as PCT International application No.

PCT/EP99/07065

on 22 September 1999

and (if applicable to U.S. or PCT application) was amended on

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number  
98870203.1

Country  
EP

Day/Month/Year Filed  
24 September 1998

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number

Date/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

Prior U.S./PCT Application(s):

Application Serial No.  
PCT/EP99/07065

Day/Month/Year Filed  
22 September 1999

Status: patented  
pending, abandoned  
Pending

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint **NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8<sup>th</sup> Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed)**, and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keerian, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffrey H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr. 29366; Mary J. Wilson, 32855; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36653; James D. Berquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta, 35329; Joseph A. Rhoads, 37515; Raymond Y. Mah, 41426; Chris Comuntzis, 31097. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, firm, or other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1. Inventor's Signature: [Signature] Date: 12 February 2001  
Inventor: Geert (first) Jannes (last) Belgium (citizenship)  
Residence: (city) Leuven (state/country) Belgium  
Post Office Address: E. Vanhoorenbekeleaan 23/1, Leuven, Belgium  
(Zip Code) B-3010
2. Inventor's Signature: [Signature] Date: \_\_\_\_\_  
Inventor: Heinz-Josef (first) Schmitt (last) German (citizenship)  
Residence: (city) Molssee (state/country) Germany  
Post Office Address: Poggenkaugsweg 1a, Molssee, Germany  
(Zip Code) D-24113

FOR ADDITIONAL INVENTORS, check box ☐ and attach sheet with same information and signature and date for each.

2732-33  
INNX-100-USNixon & Vanderhye P.C. (.  
(Domestic Non-Assigned/Foreign) P

**RULE 63 (37 C.F.R. 1.63)**  
**INVENTORS DECLARATION FOR PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) subject matter which is claimed and for which a patent is sought on the invention entitled:

**IDENTIFICATION OF MICROORGANISMS CAUSING ACUTE RESPIRATORY TRACT INFECTIONS (ARI)**

the specification of which (check applicable box(es));

☐ is attached hereto  
☐ was filed on

as U.S. Application Serial No.

(Atty Dkt. No. :

☒ was filed as PCT International application No.  
 and (if applicable to U.S. or PCT application) was amended on

PCT/EP99/07065

on 22 September 1999

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accord 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application priority is claimed or, if no priority is claimed, before the filing date of this application:

Priority Foreign Application(s):

Application Number  
98670203.1Country  
EPDay/Month/Year  
24 September

I hereby claim the benefit under 35 U.S.C. 5119(a) of any United States provisional application(s) listed below.  
 Application Number Date/Month/Year Filed

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT International applications listed above or below and, in each subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the applications and the national or PCT International filing date of this application:

Prior U.S./PCT Application(s):  
 Application Serial No.  
 PCT/EP99/07065

Day/Month/Year Filed  
 22 September 1999

Status: pate  
 pending, aband  
 Per

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are belief be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the valid application or any patent issued thereon. And on behalf of the owner(s) hereof, I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Road, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof (of the same address) individually and collectively owner's/owners' attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25540; James Hoamer, 30184; Robert W. Faris, 31352; Richard G. Busha, 22770; Mark E. Nuabeum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33353; Jeffrey H. Nelson, 30481; John R. Lastova, 33149; H. Warner Jr., 26366; Mary J. Wilson, 32966; J. Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; E. J. Sadoff, 38653; James D. Be 34778; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Preata, 19828; Joseph 5328; Joseph A. Rhoe, 37518; Raymond Y. Mah, 41426; Chris Comuncle, 31097. I also authorize Nixon & Vanderhye to delete any attorney names/numbers no longer with the firm and to act and rely solely on instructions directly communicated from the person, assignee, attorney, in other organization sending instructions to Nixon & Vanderhye on behalf of the owner(s).

1. Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_  
 Inventor: Geert (first) M Jannes (last) Belgium (citizenship)  
 Residence (city): Leuven (state/country): Belgium  
 Post Office Address: E. Vanhoorenbekeaan 23/1, Leuven, Belgium  
 (Zip Code): B-3010

2. Inventor's Signature: \_\_\_\_\_ Date: 21-02-01  
 Inventor: Heinz-Josef (first) M Schmitt (last) German (citizenship)  
 Residence (city): Molessee (state/country): Germany  
 Post Office Address: Poggenkaugeweg 1a, Molessee, Germany  
 (Zip Code): D-24113

FOR ADDITIONAL INVENTORS, check box ☐ and attach sheet with same information and signature and date for each.